Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
0.8022
Oct 21 • 9:54 AM ET Dollar change-0.0291 Percentage change(-3.50%)
Index
-
Market Cap
30.30M
Enterprise Value
-52.64M
Income
-93.46M
Sales
13.56M
Book/sh
2.98
Cash/sh
3.19
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
119
IPO
Feb 09, 2024
P/E
-
Forward P/E
-
PEG
-
P/S
2.23
P/B
0.27
P/C
0.25
P/FCF
-
EV/EBITDA
-
EV/Sales
-3.88
Quick Ratio
4.50
Current Ratio
4.50
Debt/Eq
0.34
LT Debt/Eq
0.28
Option/Short
No / Yes
EPS (ttm)
-2.49
EPS next Y
-1.88
EPS next Q
-0.64
EPS this Y
-5.63%
EPS next Y
24.61%
EPS next 5Y
7.64%
EPS past 3/5Y
-26.57% -42.49%
Sales past 3/5Y
13.59% 219.15%
EPS Y/Y TTM
-5.97%
Sales Y/Y TTM
-59.84%
EPS Q/Q
-36.21%
Sales Q/Q
-103.02%
Insider Own
21.07%
Insider Trans
0.11%
Inst Own
16.39%
Inst Trans
-1.46%
ROA
-41.91%
ROE
-60.61%
ROIC
-64.88%
Gross Margin
61.92%
Oper. Margin
-741.58%
Profit Margin
-689.20%
SMA20
-18.46%
SMA50
-27.19%
SMA200
-39.53%
Trades
Shs Outstand
37.78M
Shs Float
29.82M
52W High
3.38 -76.27%
52W Low
0.77 4.32%
Volatility
7.96% 6.20%
ATR (14)
0.06
RSI (14)
26.37
Beta
0.73
Rel Volume
1.10
Avg Volume
156.42K
Volume
19,079
Perf Week
-6.85%
Perf Month
-29.63%
Perf Quarter
-34.25%
Perf Half Y
-45.80%
Perf YTD
-50.48%
Perf Year
-74.53%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
0.83
Price
0.80
Change %
-3.50%
Date Action Analyst Rating Change Price Target Change
Jul-07-26Resumed Chardan Capital Markets Buy $5
May-07-24Initiated H.C. Wainwright Buy $10
May-02-24Downgrade JP Morgan Overweight → Neutral $16 → $6
Mar-05-24Initiated Wells Fargo Overweight $25
Mar-05-24Initiated TD Cowen Outperform
Mar-05-24Initiated JP Morgan Overweight $16
Mar-05-24Initiated Jefferies Buy $23
Mar-05-24Initiated Chardan Capital Markets Buy $21
Mar-05-24Initiated BMO Capital Markets Outperform $22
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Reid LaurenceDirectorSep 09 '26Buy1.1720,00023,40120,000Sep 11 07:51 PM
Wein MatthewSee RemarksSep 08 '26Sale1.16358415126,133Sep 10 03:47 PM
Irish JianSee RemarksSep 08 '26Sale1.162,1402,479375,393Sep 10 03:40 PM
Wapnick PamelaChief Financial OfficerSep 08 '26Sale1.161,9112,214206,580Sep 10 03:34 PM
Wapnick PamelaChief Financial OfficerJun 05 '26Sale1.302,8843,746208,491Jun 10 11:23 AM
Irish JianSee RemarksJun 05 '26Sale1.303,7374,854377,533Jun 10 11:21 AM
Wein MatthewSee RemarksJun 05 '26Sale1.30558725126,491Jun 10 11:19 AM
Wapnick PamelaChief Financial OfficerMar 05 '26Sale1.601,5812,530187,375Mar 09 05:16 PM
Wein MatthewSee RemarksMar 05 '26Sale1.60482771114,549Mar 09 05:16 PM
Irish JianChief Executive OfficerMar 05 '26Sale1.601,6072,571333,770Mar 09 05:15 PM
Thomas Brian C.DirectorDec 05 '25Sale1.773,8306,7862,510,960Dec 08 01:56 PM
Wein MatthewSee RemarksDec 05 '25Sale1.77199353115,031Dec 08 01:51 PM
Wapnick PamelaChief Financial OfficerDec 05 '25Sale1.771,5762,793188,956Dec 08 01:49 PM
Irish JianChief Executive OfficerDec 05 '25Sale1.771,6022,839563,839Dec 08 01:38 PM
Metagenomi Therapeutics, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.
Ph.D.Dr. Jian Irish M.B.A.
Chief Financial OfficerMs. Pamela M. Wapnick M.B.A.
Gen-er-al Coun-selMr. Matthew L. Wein J.D.
Co-Founder & Member of Scientific Advisory BoardDr. Joseph Knowles M.D.
Senior Vice Pres-i-dent of Tech-ni-cal Devel-op-ment & Oper-a-tionsMr. Mark Leonard